Sol-Gel Technologies plans to expand the use of its lead drug candidate, SGT-610, for high-frequency basal cell carcinoma, potentially doubling its commercial potential. Health Canada approved EPSOLAY in September 2025. Sol-Gel also signed an agreement with Viatris for EPSOLAY and TWYNEO in Australia and New Zealand. The company reported financial results for the third quarter of 2025, showing a net loss of $5.9 million. Sol-Gel expects to launch TWYNEO and EPSOLAY in new territories in 2027 and 2028, respectively, with potential annual revenue of up to $10 million by 2031. The company is focused on advancing treatments for rare dermatological diseases.

Read more at GlobeNewswire: Sol-Gel Reports Third Quarter 2025 Financial Results and